Introduction and history
Cardiac troponin I (CTnI) is part of the troponin complex integral to myocardial contraction. During myocyte necrosis or membrane damage CTnI leaks into the circulation and is detectable in the serum (gold standard to detect myocardial injury in man [Anon 2014 ], correlated to severity and prognosis in dogs and man [Fonfara et al. 2010] ), but provides no information on the mechanism of injury. Genetic sequencing of equine CTnI confirms that use of commercial human immunoassays is appropriate (Rishniw and Simpson 2005) .
Search method
The search terms 'horse' or 'equine' and 'cardiac troponin I' were entered into Pubmed (http://www.ncbi.nlm.nih.gov/ pubmed).
Search outcome
(1) Quantity of evidence: A total of 54 papers were retrieved; 31 provided useful information and 23 were discarded as irrelevant to the question (16), provided a low level of evidence (six case reports) or a secondary source (one review article). (2) Quality of evidence: There were eight case-control studies, seven cross-sectional studies, 11 case series and six experimental studies providing moderate evidence for the conclusions.
How has CTnI been validated for use in the horse?
Normal values in healthy animals Multiple studies have generated reference ranges for CTnI from clinically healthy horses (Phillips et al. 2003; Van Der Vekens et al. 2015a,b) . In the majority of these studies a clinical examination and ECG were not performed and therefore cardiac disease could have been overlooked. Importantly, there were significant differences between values obtained from different assays in different laboratories that precludes quantifiable comparison between published studies (Serra et al. 2010; Van Der Vekens et al. 2015a Evaluation in horses presenting with myocardial disease A diagnostic test should undergo an independent, blind comparison with a reference standard (for CTnI, clinical evaluation and an ECG). These four studies of horses presenting for cardiac disease separately to healthy animals (case-control studies) may overestimate the accuracy of the test (due to bias, Table 1 ).
The findings of these studies are consistent and conclude an increase in CTnI with primary active myocardial disease, but not necessarily with secondary disease where myocyte injury may not always occur.
Diagnosis of myocardial damage for horses presenting with other pathologies
A wide of range of pathologies have been evaluated for evidence of myocardial injury providing a population with less bias as these horses may have not presented with symptoms of cardiac disease. 
Conclusion
There is a clear and well documented relationship between myocardial injury and increased CTnI in horses. There may be a correlation between both the degree and duration of this increase and severity of injury/prognosis but further work is required to define this relationship. CTnI should be measured in all horses presenting with myocardial disease and in any pathology where myocardial injury can occur.
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